Login / Signup

Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Jack William O'Sullivan
Published in: BMJ evidence-based medicine (2019)
Keyphrases
  • cardiovascular disease
  • type diabetes
  • glycemic control
  • cardiovascular risk factors
  • metabolic syndrome
  • adipose tissue
  • skeletal muscle